Skip to main content

An official website of the United States government

You have 2 new alerts

Gene Targeting Vector Services through Ozgene Pty Ltd

Looking for contract opportunity help?

APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.

APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.

The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).

General Information

  • Contract Opportunity Type: Presolicitation (Original)
  • Original Published Date: Jul 19, 2022 01:32 pm EDT
  • Original Response Date: Jul 26, 2022 05:00 pm EDT
  • Inactive Policy: 15 days after response date
  • Original Inactive Date:
  • Initiative:
    • None

Classification

  • Original Set Aside:
  • Product Service Code: Q301 - MEDICAL- LABORATORY TESTING
  • NAICS Code:
    • 541380 - Testing Laboratories
  • Place of Performance:
    Bethesda , MD 20892
    USA

Description

PRE-SOLICITATION NOTICE - NOTICE OF INTENT

NOI-NIAID-2136123

NAICS – 541380, Testing Laboratories

This is a Notice of Intent, not a request for proposal.  The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Ozgene Pty Ltd, located in Bentley, Australia, to procure gene targeting vector services to be used to investigate biologically relevant functions of JAK1 during defective mucosal immunity to C. albincans in STAT1 GOF. 

The National Institute of Allergy and Infectious Diseases (NIAID) Fungal Pathogenesis Section (FPS) research is broadly focused on characterization of immune response against debilitating fungal infections with an aim to improve patient outcomes via identifying at-risk patient population for early prophylaxis and uncover novel molecules that will aid in development of new immunotherapeutic modalities.  This project is focused on understanding the pathophysiological mechanisms of STAT1 GOF mutations associated with defective mucosal immunity to C. albicans. This project has important implications in the medical mycology and mucosal immunology fields for: i) the possible development of novel therapeutic strategies based on the understanding of the pathophysiology mechanisms of STAT1 GOF mutations in mice; ii) the discovery of novel biomarkers for diagnostics; iii) better genetic counselling; and iv) better follow-up and outcomes of the patients.  A strong motivation to establish this mouse model through Ozgene’s gene targeting vector services is for the generation of a conditional knockout mouse that allows a temporally and spatially controlled Jak1 gene expression in somatic tissues. This is as a follow-on to projects and studies previously conducted by Ozgene Pty Ltd in the scope of a larger project.

The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL.  All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2136123 to Dana Monroe at dana.monroe@nih.gov, by 5:00 pm eastern standard time July 26, 2022.  All responses received by the closing date of this synopsis will be considered by the Government.  A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

Contact Information

Contracting Office Address

  • 5601 FISHERS LANE, SUITE 3D11
  • BETHESDA , MD 20892
  • USA

Primary Point of Contact

Secondary Point of Contact





History

  • Aug 10, 2022 11:55 pm EDTPresolicitation (Original)